Leukemia and lymphoma in pregnancy

Treatment of pregnant women with chemotherapy may pose a risk to the fetus, raising therapeutic, ethical, moral, and social dilemmas. Publications on this issue are limited to retrospective series and case reports, thus further complicating decision making. Diagnosis and staging are usually performe...

Full description

Saved in:
Bibliographic Details
Published inHematology/oncology clinics of North America Vol. 25; no. 2; p. 277
Main Authors Abadi, Uri, Koren, Gideon, Lishner, Michael
Format Journal Article
LanguageEnglish
Published United States 01.04.2011
Subjects
Age Factors
Female
Humans
Incidence
Leukemia - epidemiology
Leukemia - physiopathology
Leukemia - therapy
Lymphoma - epidemiology
Lymphoma - physiopathology
Lymphoma - therapy
Male
Maternal-Fetal Exchange
Pregnancy
Pregnancy Complications, Hematologic - epidemiology
Pregnancy Complications, Hematologic - physiopathology
Pregnancy Complications, Hematologic - therapy
Pregnancy Complications, Neoplastic - epidemiology
Pregnancy Complications, Neoplastic - physiopathology
Pregnancy Complications, Neoplastic - therapy
Online AccessGet more information

Cover

More Information
Summary:Treatment of pregnant women with chemotherapy may pose a risk to the fetus, raising therapeutic, ethical, moral, and social dilemmas. Publications on this issue are limited to retrospective series and case reports, thus further complicating decision making. Diagnosis and staging are usually performed as in nonpregnant women, but procedures that expose the fetus to radiation are excluded. Chemotherapy is not recommended in the first trimester to avoid fetal malformations. Thus, the option is either treatment delay or pregnancy termination. Later in pregnancy, treatment is often initiated without delay, with no apparent evidence of teratogenicity.
ISSN:1558-1977
DOI:10.1016/j.hoc.2011.01.001